The Special Advisory Council consists of a select team of thought leaders with specific expertise across various disciplines to help BioPharmX embrace patient centricity in its products, pricing, and across market access considerations.
The advisors bring decades of experience in fields ranging from regulatory pathways to market access and from infectious diseases to antibiotic resistance. Collaborating with the company’s scientific and medical teams and Medical Advisory Board, these special advisors inform the company’s efforts by providing the kind of strategic expertise needed to position the company as a leader in patient-centric dermatology.
R. Todd Plott, MD
Dr. R. Todd Plott is an experienced developer of prescription pharmaceutical drugs who has helped small and large companies create their own products. He has been involved in nine different development programs that have received approval by the U.S. Food and Drug Administration (FDA) and other international regulatory agencies. He personally led and supervised five of these programs from initiation through approval. Establishing and leading teams of experts focused on New Drug Application (NDA) approval has been Dr. Plott’s strength. During his 15 years in the industry, he has built the development and regulatory departments of companies from ground up, hiring experts in formulation, preclinical, clinical, and regulatory affairs to form departments that produced results. One his best-known contributions to dermatology and most challenging engagement was the development of an extended-release minocycline for the treatment of acne vulgaris, SOLODYN™, the first oral antibiotic designed and approved by the FDA for the treatment of acne vulgaris.
Mark D. Kaufmann, MD
Dr. Mark Kaufmann, associate clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City and chief medical officer of Tricenna Dermatology Group, is a director of the American Academy of Dermatology, and serves on many academy committees, including as an advisor to the Academy Relative Value Update Committee (RUC) team. Dr. Kaufman has published many articles on the topic of health information technology and is a frequent lecturer at the annual meetings of the AAD and other societies, and grand rounds. His contributions have been recognized by AAD Presidential Citations in 2013, 2014, 2015, and 2017.
George G. Zhanel, Ph.D.
Dr. George G. Zhanel, a professor in the Department of Medical Microbiology/Infectious Diseases, Rady College of Medicine at the University of Manitoba, is the coordinator of Antibiotic Resistance in the Departments of Medicine and Clinical Microbiology, Health Sciences Centre, and director of the Canadian Antimicrobial Resistance Alliance (CARA). He is also the founding and chief editor of the Canadian Antimicrobial Resistance Alliance (CARA) website. The author of more than 1,000 published papers, chapters and abstracts in the area of antimicrobial resistant infections, Dr. Zhanel is a globally recognized expert on antimicrobials and antimicrobial resistance. He has been involved in the development of treatment guidelines for a variety of infectious diseases and is interested in antimicrobial usage/resistance in humans, animals and food and the impact of antimicrobial exposure on human and animal microbiomes.
Kenneth J. Tomecki, MD, FAAD
Dr. Kenneth J. Tomecki, vice chairman of the Department of Dermatology at Cleveland Clinic and a clinical assistant professor at Case Western Reserve University School of Medicine, is one of the nation’s leading authorities on infectious diseases. He has a passion for patient-centric care, clinical research and medical education, and he has developed continuing medical education programs in medical/surgical dermatology and therapy. Former president of the Fellows of the American Academy of Dermatology, Dr. Tomecki has held several officer positions with the AAD and has served on numerous AAD committees. During his 30-year career, he has published hundreds of articles, book chapters, abstracts and presentations. His contributions have been recognized by an AAD Presidential Citation in 2016 and by his being named an honorary member of the Czech Academy of Dermatology and Venerealogy and the Mexican Academy of Dermatology.
James J. Leyden, MD
Dr. James J. Leyden, emeritus professor of Dermatology at the University of Pennsylvania, has been a consultant to the Food and Drug Administration, the Federal Trade Commission and to drug regulation agencies in England, Germany and Austria. A past member of the American Academy of Dermatology Board of Directors and former chairman of the Board of the Dermatology Foundation, his research has focused on a variety of clinical problems, including bacterial and fungal infections, acne, aging and photoaging, and developing methodologies for in-vivo evaluation of anti-microbial effects. He has studied mechanisms of inflammation in acne, bacterial taxonomy and bacterial production of body odors. Dr. Leyden has also been instrumental in developing, testing and commercializing Retin-A, Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin and Minocin. He is internationally recognized for his contributions to dermatology, particularly to the understanding of the pathophysiology, diagnosis and treatment of acne and rosacea.